Constitutive activation of JAK2 in mammary epithelium elevates Stat5 signalling, promotes alveologenesis and resistance to cell death, and contributes to tumourigenesis

Cell Death and Differentiation

Volumn 19, Issue 3, 2012, Pages 511-522

  Caffarel, M M ^a   Zaragoza, R ^a,b   Pensa, S ^a   Li, J ^c   Green, A R ^c   Watson, C J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF VALENCIA   (Spain)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

breast cancer; JAK Stat signalling; JAK2 V617F; mammary gland development; Stat5

Indexed keywords

JANUS KINASE 2; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST DEVELOPMENT; BREAST EPITHELIUM; CANCER MODEL; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; BREAST NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; FEMALE; HUMANS; JANUS KINASE 2; LACTATION; MALE; MAMMARY GLANDS, ANIMAL; MAMMARY GLANDS, HUMAN; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, KNOCKOUT; MICE, NUDE; MUTATION, MISSENSE; NEOPLASM TRANSPLANTATION; PREGNANCY; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TRANSPLANTATION, HETEROLOGOUS;

MUS MUSCULUS;

EID: 84857053130     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2011.122     Document Type: Article

References (40)

1. Yamaji D, Na R, Feuermann Y, Pechhold S, Chen W, Robinson GW et al. Development of mammary luminal progenitor cells is controlled by the transcription factor STAT5A. Genes Dev 2009; 23: 2382-2387.
2. Watson CJ, Neoh K. The Stat family of transcription factors have diverse roles in mammary gland development. Semin Cell Dev Biol 2008; 19: 401-406.
3. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: New surprises in the Jak/Stat pathway. Cell 2002; 109 (Suppl): S121-S131. (Pubitemid 34457857)
4. Wagner KU, Krempler A, Triplett AA, Qi Y, George NM, Zhu J et al. Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. Mol Cell Biol 2004; 24: 5510-5520. (Pubitemid 38738182)
5. Sakamoto K, Lin WC, Triplett AA, Wagner KU. Targeting janus kinase 2 in Her2/neuexpressing mammary cancer: Implications for cancer prevention and therapy. Cancer Res 2009; 69: 6642-6650.
6. Sakamoto K, Triplett AA, Schuler LA, Wagner KU. Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer. Oncogene 2010; 29: 5359-5369.
7. Yu H, Jove R. The STATs of cancer -new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105. (Pubitemid 38198738)
8. Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R et al. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 2006; 12: 20-28. (Pubitemid 43166171)
9. Cotarla I, Ren S, Zhang Y, Gehan E, Singh B, Furth PA. Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 2004; 108: 665-671. (Pubitemid 38076397)
10. Barbieri I, Pensa S, Pannellini T, Quaglino E, Maritano D, Demaria M et al. Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res 2010; 70: 2558-2567.
11. Vafaizadeh V, Klemmt P, Brendel C, Weber K, Doebele C, Britt K et al. Mammary epithelial reconstitution with gene-modified stem cells assigns roles to Stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation. Stem Cells 2010; 28: 928-938.
12. Croker BA, Kiu H, Nicholson SE. SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol 2008; 19: 414-422.
13. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW et al. Genome remodelling in a basallike breast cancer metastasis and xenograft. Nature 2010; 464: 999-1005.
14. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007; 7: 673-683. (Pubitemid 47327415)
15. Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 2006; 66: 11156-11165. (Pubitemid 46009942)
16. Hookham MB, Elliott J, Suessmuth Y, Staerk J, Ward AC, Vainchenker W et al. The myeloproliferative disorder-Associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 2007; 109: 4924-4929. (Pubitemid 46827790)
17. Li J, Spensberger D, Ahn JS, Anand S, Beer PA, Ghevaert C et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 2010; 116: 1528-1538.
18. Dunbar ME, Dann P, Brown CW, Van Houton J, Dreyer B, Philbrick WP et al. Temporally regulated overexpression of parathyroid hormone-related protein in the mammary gland reveals distinct fetal and pubertal phenotypes. J Endocrinol 2001; 171: 403-416. (Pubitemid 34026356)
19. Woodward WA, Chen MS, Behbod F, Rosen JM. On mammary stem cells. J Cell Sci 2005; 118 (Part 16): 3585-3594. (Pubitemid 41309406)
20. Choi YS, Chakrabarti R, Escamilla-Hernandez R, Sinha S. Elf5 conditional knockout mice reveal its role as a master regulator in mammary alveolar development: Failure of Stat5 activation and functional differentiation in the absence of Elf5. Dev Biol 2009; 329: 227-241.
21. Li S, Rosen JM. Nuclear factor I and mammary gland factor (STAT5) play a critical role in regulating rat whey acidic protein gene expression in transgenic mice. Mol Cell Biol 1995; 15: 2063-2070.
22. Oakes SR, Naylor MJ, Asselin-Labat ML, Blazek KD, Gardiner-Garden M, Hilton HN et al. The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes Dev 2008; 22: 581-586. (Pubitemid 351342431)
23. Uria JA, Werb Z. Matrix metalloproteinases and their expression in mammary gland. Cell Res 1998; 8: 187-194. (Pubitemid 128544279)
24. Clarkson RW, Boland MP, Kritikou EA, Lee JM, Freeman TC, Tiffen PG et al. The genes induced by signal transducer and activators of transcription (STAT)3 and STAT5 in mammary epithelial cells define the roles of these STATs in mammary development. Mol Endocrinol 2006; 20: 675-685. (Pubitemid 43291217)
25. Gordon KE, Binas B, Chapman RS, Kurian KM, Clarkson RW, Clark AJ et al. A novel cell culture model for studying differentiation and apoptosis in the mouse mammary gland. Breast Cancer Res 2000; 2: 222-235. (Pubitemid 32223589)
26. Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K et al. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 1999; 13: 2604-2616. (Pubitemid 29489651)
27. Khaled WT, Read EK, Nicholson SE, Baxter FO, Brennan AJ, Came PJ et al. The IL-4/IL-13/Stat6 signalling pathway promotes luminal mammary epithelial cell development. Development 2007; 134: 2739-2750. (Pubitemid 47307230)
28. Kuraishi T, Mizoguchi Y, Sun Y, Aoki F, Imakawa K, Sakai S. The casein mRNA decay changes in parallel with the poly(A) tail length in the mouse mammary gland. Mol Cell Endocrinol 2002; 190: 101-107. (Pubitemid 34462055)
29. Burdon TG, Maitland KA, Clark AJ, Wallace R, Watson CJ. Regulation of the sheep beta-lactoglobulin gene by lactogenic hormones is mediated by a transcription factor that binds an interferon-gamma activation site-related element. Mol Endocrinol 1994; 8: 1528-1536. (Pubitemid 24370201)
30. Harris J, Stanford PM, Sutherland K, Oakes SR, Naylor MJ, Robertson FG et al. Socs2 and elf5 mediate prolactin-induced mammary gland development. Mol Endocrinol 2006; 20: 1177-1187.
31. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
32. Wagner KU, Rui H. Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression. J Mammary Gland Biol Neoplasia 2008; 13: 93-103.
33. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009; 16: 487-497.
34. Chen E, Beer PA, Godfrey AL, Ortmann CA, Li J, Costa-Pereira AP et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell 2010; 18: 524-535.
35. Iavnilovitch E, Groner B, Barash I. Overexpression and forced activation of stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis. Mol Cancer Res 2002; 1: 32-47. (Pubitemid 36330209)
36. Park DS, Lee H, Frank PG, Razani B, Nguyen AV, Parlow AF et al. Caveolin-1-deficient mice show accelerated mammary gland development during pregnancy, premature lactation, and hyperactivation of the Jak-2/STAT5a signaling cascade. Mol Biol Cell 2002; 13: 3416-3430. (Pubitemid 35191364)
37. Haffner MC, Petridou B, Peyrat JP, Revillion F, Muller-Holzner E, Daxenbichler G et al. Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer 2007; 7: 136.
38. Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 2010; 70: 3119-3127.
39. Fernandez I, Touraine P, Goffin V. Prolactin and human tumourogenesis. J Neuroendocrinol 2010; 22: 771-777.
40. Hayashi K, Matsuda S, Machida K, Yamamoto T, Fukuda Y, Nimura Y et al. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res 2001; 61: 2361-2364. (Pubitemid 32685805)